PIDILITIND Q4 FY26 Guidance vs Delivery (PIDILITIND Management Mirror)

Volume Growth & Topline Demand

In the Mar'26 Qtr, management refrained from providing explicit full-year Underlying Volume Growth (UVG) guidance due to unprecedented geopolitical volatility, a shift from the Dec'25 Qtr where they confidently projected continuous UVG improvement and expected total B2B growth to return to mid-teens. Despite this near-term withdrawal of explicit targets, the long-term strategic focus on sustaining double-digit UVG and systematically expanding it by 100 basis points remains intact, continuing the robust domestic volume momentum initially cited in the Sep'25 Qtr. [Status: Withdrawn]